Madrigal Pharma

Forecast & Rating19 analysts currently cover Madrigal Pharma, with about 94.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $685.22, about 56.5% upside from the current price of $437.74. Price targets range from $533.00 to $962.00 — a wide spread, showing clear disagreement over just how much Madrigal Pharma can rise. Historically, about 89.5% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Madrigal Pharma closely still see room for the stock to rise. Data as of Oct 26, 2026; for reference only and not investment advice.